Trials / Not Yet Recruiting

Not Yet RecruitingNCT06823050

A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC

A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced Hepatocellular Carcinoma with the DEB-TACE (drug-loaded Microsphere Transcatheter Arterial Chemoembolization) Combined with Hepatic Artery Perfusion of Raltitrexed and Oxaliplatin (SALOX-HAIC) Regimen

Status: Not Yet Recruiting
Phase: —
Study type: Observational
Enrollment: 59 (estimated)

Sponsor: Xuhua Duan · Academic / Other
Sex: All
Age: 18 Years – 80 Years
Healthy volunteers: Not accepted

Summary

The aim of this study is to clarify the safety and efficacy of DEB-TACE combined with SALOX-HAIC in the treatment of unresectable advanced primary liver cancer. To determine whether this therapy can prolong the indicators such as PFS, TTP, OS, ORR, and DOR.

Conditions

Hepatocellular Carcinoma

Timeline

Start date: 2025-03-01
Primary completion: 2026-03-01
Completion: 2028-02-28
First posted: 2025-02-12
Last updated: 2025-02-12

Locations

7 sites across 1 country: China

Source: ClinicalTrials.gov record NCT06823050. Inclusion in this directory is not an endorsement.